150 related articles for article (PubMed ID: 32687746)
1. In older adults, new use of allopurinol or febuxostat was linked to hypersensitivity reactions versus colchicine.
Schattner A
Ann Intern Med; 2020 Jul; 173(2):JC10. PubMed ID: 32687746
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2020 Apr; 79(4):529-535. PubMed ID: 32024648
[TBL] [Abstract][Full Text] [Related]
3. Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Ma KS; Wei JC; Chung WH
Ann Rheum Dis; 2022 Jun; 81(6):e107. PubMed ID: 32561605
[No Abstract] [Full Text] [Related]
4. Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma
Singh JA
Ann Rheum Dis; 2022 Jun; 81(6):e108. PubMed ID: 32561599
[No Abstract] [Full Text] [Related]
5. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Alten R; Mischkewitz M; Nitschmann S
Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
[No Abstract] [Full Text] [Related]
6. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland.
Quilis N; Vela P; Blanco Cáceres BA; Diaz-Torne C; Calvo-Aranda E; Sivera F; Prada-Ojeda A; Pérez Ruiz F; Pascual E; Andrés M
Ann Rheum Dis; 2022 Jul; 81(7):e124. PubMed ID: 32616605
[No Abstract] [Full Text] [Related]
7. Confounding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Hsu PK; Lee YH; Wei JCC
Ann Rheum Dis; 2022 Jul; 81(7):e122. PubMed ID: 32561600
[No Abstract] [Full Text] [Related]
8. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu
Singh JA
Ann Rheum Dis; 2022 Jul; 81(7):e123. PubMed ID: 32561601
[No Abstract] [Full Text] [Related]
9. Cross-Reactions Between Allopurinol and Febuxostat.
Lien YH; Logan JL
Am J Med; 2017 Feb; 130(2):e67-e68. PubMed ID: 27667702
[No Abstract] [Full Text] [Related]
10. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
[TBL] [Abstract][Full Text] [Related]
12. Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills
Singh JA
Ann Rheum Dis; 2022 Jul; 81(7):e125. PubMed ID: 32616606
[No Abstract] [Full Text] [Related]
13. Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease.
Lee JS; Won J; Kwon OC; Lee SS; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
J Rheumatol; 2019 May; 46(5):527-531. PubMed ID: 30442825
[TBL] [Abstract][Full Text] [Related]
14. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
Bardin T; Chalès G; Pascart T; Flipo RM; Korng Ea H; Roujeau JC; Delayen A; Clerson P
Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
[TBL] [Abstract][Full Text] [Related]
15. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of anti-gout agents: an update.
Stamp LK
Curr Opin Rheumatol; 2014 Mar; 26(2):162-8. PubMed ID: 24378930
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2017 Oct; 76(10):1669-1678. PubMed ID: 28584186
[TBL] [Abstract][Full Text] [Related]
19. Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial.
Ghang B; Ahn SM; Kim J; Kim YG; Lee CK; Yoo B
Rheumatology (Oxford); 2020 Jun; 59(6):1439-1440. PubMed ID: 31748801
[No Abstract] [Full Text] [Related]
20. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
Singh JA; Cleveland JD
Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
